Ástralía - enska - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - carbidopa monohydrate, quantity: 40.5 mg (equivalent: carbidopa, qty 37.5 mg); entacapone, quantity: 200 mg; levodopa, quantity: 150 mg - tablet, film coated - excipient ingredients: trehalose dihydrate; hyprolose; magnesium stearate; microcrystalline cellulose; sodium sulfate; carmellose sodium; powdered cellulose; titanium dioxide; purified talc; iron oxide yellow; iron oxide red; polyvinyl alcohol; macrogol 3350; lecithin - levodopa/carbidopa/entacapone is indicated for the management of patients with parkinson?s disease who are experiencing motor fluctuations.

Ástralía - enska - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - carbidopa monohydrate, quantity: 33.75 mg (equivalent: carbidopa, qty 31.25 mg); entacapone, quantity: 200 mg; levodopa, quantity: 125 mg - tablet, film coated - excipient ingredients: trehalose dihydrate; microcrystalline cellulose; hyprolose; magnesium stearate; powdered cellulose; carmellose sodium; sodium sulfate; titanium dioxide; purified talc; iron oxide yellow; iron oxide red; polyvinyl alcohol; macrogol 3350; lecithin - levodopa/carbidopa/entacapone is indicated for the management of patients with parkinson?s disease who are experiencing motor fluctuations.

Ástralía - enska - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - carbidopa monohydrate, quantity: 54.1 mg (equivalent: carbidopa, qty 50 mg); levodopa, quantity: 200 mg; entacapone, quantity: 200 mg - tablet, film coated - excipient ingredients: mannitol; titanium dioxide; sucrose; magnesium stearate; croscarmellose sodium; glycerol; povidone; iron oxide red; maize starch; hypromellose; polysorbate 80 - l.c.e. sandoz 200/50/200 is indicated for the management of patients with parkinson's disease who are experiencing motor fluctuations.

Ástralía - enska - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - carbidopa monohydrate, quantity: 33.8 mg (equivalent: carbidopa, qty 31.25 mg); levodopa, quantity: 125 mg; entacapone, quantity: 200 mg - tablet, film coated - excipient ingredients: glycerol; titanium dioxide; croscarmellose sodium; sucrose; magnesium stearate; polysorbate 80; mannitol; maize starch; povidone; iron oxide red; hypromellose - l.c.e. sandoz 125/31.25/200 is indicated for the management of patients with parkinson's disease who are experiencing motor fluctuations.

Ástralía - enska - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - carbidopa monohydrate, quantity: 27 mg (equivalent: carbidopa, qty 25 mg); levodopa, quantity: 100 mg; entacapone, quantity: 200 mg - tablet, film coated - excipient ingredients: povidone; iron oxide yellow; croscarmellose sodium; mannitol; glycerol; maize starch; titanium dioxide; magnesium stearate; polysorbate 80; hypromellose; sucrose; iron oxide red - l.c.e. sandoz 100/25/200 is indicated for the management of patients with parkinson's disease who are experiencing motor fluctuations.

Ástralía - enska - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - levodopa, quantity: 50 mg; carbidopa monohydrate, quantity: 13.5 mg (equivalent: carbidopa, qty 12.5 mg); entacapone, quantity: 200 mg - tablet, film coated - excipient ingredients: hypromellose; mannitol; titanium dioxide; magnesium stearate; povidone; maize starch; sucrose; iron oxide red; glycerol; iron oxide yellow; polysorbate 80; croscarmellose sodium - l.c.e. sandoz 50/12.5/200 is indicated for the management of patients with parkinson's disease who are experiencing motor fluctuations.

Malta - enska - Medicines Authority

fair-med healthcare gmbh planckstr. 13, 22765 hamburg, germany - carbidopa, levodopa - tablet - carbidopa 27 mg levodopa 100 mg - anti-parkinson drugs

Malta - enska - Medicines Authority

fair-med healthcare gmbh planckstr. 13, 22765 hamburg, germany - levodopa, carbidopa - tablet - levodopa 27 mg carbidopa 250 mg - anti-parkinson drugs

Bandaríkin - enska - NLM (National Library of Medicine)

ethex - carbidopa (unii: mnx7r8c5vo) (carbidopa - unii:mnx7r8c5vo), levodopa (unii: 46627o600j) (levodopa - unii:46627o600j) - tablet, extended release - 50 mg - carbidopa and levodopa extended-release tablets are indicated in the treatment of the symptoms of idiopathic parkinson’s disease (paralysis agitans), postencephalitic parkinsonism, and symptomatic parkinsonism which may follow injury to the nervous system by carbon monoxide intoxication and/or manganese intoxication. nonselective mao inhibitors are contraindicated for use with carbidopa and levodopa extended-release tablets. these inhibitors must be discontinued at least two weeks prior to initiating therapy with carbidopa and levodopa extended-release tablets. carbidopa and levodopa extended-release tablets may be administered concomitantly with the manufacturer’s recommended dose of an mao inhibitor with selectivity for mao type b (e.g., selegiline hcl) (see precautions, drug interactions ). carbidopa and levodopa extended-release tablets are contraindicated in patients with known hypersensitivity to any component of this drug and in patients with narrow-angle glaucoma. because levodopa may activate a mali

Bandaríkin - enska - NLM (National Library of Medicine)

mckesson corporation dba sky packaging - carbidopa (unii: mnx7r8c5vo) (carbidopa anhydrous - unii:kr87b45rgh), levodopa (unii: 46627o600j) (levodopa - unii:46627o600j) - carbidopa anhydrous 10 mg - carbidopa and levodopa tablets usp are indicated in the treatment of parkinson's disease post-encephalitic parkinsonism, and symptomatic parkinsonism that may follow carbon monoxide intoxication or manganese intoxication. carbidopa allows patients treated for parkinson's disease to use much lower doses of levodopa. some patients who responded poorly to levodopa have improved on carbidopa and levodopa tablets usp. this is most likely due to decreased peripheral decarboxylation of levodopa caused by administration of carbidopa rather than by a primary effect of carbidopa on the nervous system. carbidopa has not been shown to enhance the intrinsic efficacy of levodopa. carbidopa may also reduce nausea and vomiting and permit more rapid titration of levodopa. nonselective monoamine oxidase (mao) inhibitors are contraindicated for use with carbidopa and levodopa. these inhibitors must be discontinued at least two weeks prior to initiating therapy with carbidopa and levodopa. carbidopa and levodopa may be administe